KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.
1. A method of detecting a mutation at position 4321 in the nucleic acid molecule of SEQ ID NO: 1 or 2 in a sample, the method comprising:
(a) contacting a sample with a probe consisting of 10 to 50 nucleotides for the detection of said mutation, wherein said probe hybridizes under high stringency conditions to any of the polynucleotide sequences (i), (ii), (iii), (iv), or (v):
(i) a polynucleotide sequence selected from nucleotides 1 to 9104 of SEQ ID NO: 1 or 2;
(ii) a polynucleotide sequence selected from nucleotides 1 to 7584 of SEQ ID NO: 1 or 2;
(iii) a polynucleotide sequence selected from nucleotides 1 to 7581 of SEQ ID NO: 1 or 2;
(iv) a polynucleotide sequence selected from a nucleotide sequence coding for the protein sequence of SEQ ID NO:8 or 9 or for the protein sequence of SEQ ID NO:8 or 9 containing at least one of the mutations depicted in SEQ ID NO: 1 or 2; or
(v) a polynucleotide sequence selected from a nucleotide sequence complementary to any of the nucleotide sequences of (i), (ii), (iii), or (iv):
wherein the polynucleotide sequence codes for the protein sequence of SEQ ID NO. 8 or 9 containing a mutation at position 1441, and wherein said high stringency conditions comprise hybridization at 68° C. in a solution comprising 50% formamide, 5×SSC (Sodium and sodium Citrate buffer) or 5× SSPE (Sodium, Sodium Phosphate, and EDTA buffer at pH 7.7), 5× Denhardt's solution, 1% Sodium Dodecyl Sulfate (SDS), and 100 μg/ml denatured salmon sperm DNA, followed by washing at 68° C. in a buffer comprising 0.2 SSC and 0.1% SDS, and
(b) detecting the presence of the mutation in the nucleic acid of the sample.
2. The method of claim 1 , wherein the sample is selected from
(a) a biopsy from human tissue or cells; or
(b) RNA or DNA from a biopsy from human tissue or cells.
3. The method of claim 1 , wherein the detecting of the mutation comprises Southern blot hybridization, Northern blot hybridization, PCR, RT-PCR, real-time RT-PCR or automated sequencing.
4. The method of claim 1 , wherein the detecting of the mutation comprises radiography, fluorescence, chemiluminescence, or any combination thereof.
5. The method of claim 1 , wherein the method is carried out on an array.
6. The method of claim 1 , wherein the method is carried out in a robotics system.
7. The method of claim 1 , wherein the method is carried out using microfluidics.
8. The method of claim 1 , wherein said probe consists of 10 to 35 nucleotides.
9. The method of claim 1 , wherein said probe consists of 20 to 35 nucleotides.
10. The method of claim 2 , wherein said sample is from the brain.
11. The method of claim 10 , wherein said sample is from putamen or substantia nigra.
12. The method of claim 2 , wherein said sample is from heart, lung, or blood lymphocytes.
13. The method of claim 2 , wherein said RNA or DNA is from the brain.
14. The method of claim 13 , wherein said RNA or DNA is from putamen or substantia nigra.
15. The method of claim 2 , wherein said RNA or DNA is from heart, lung, or blood lymphocytes.
16. The method of claim 1 , wherein said method is diagnostic of a neurodegenerative disorder selected from the group consistent of Parkinson disease (PD), sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), synucleinopathy, and tauopathy.